Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bennett Fein

Gastroenterology Martinsville, VA Medical Doctor

NPI 1033265848 CMS profile 228389

319 Hospital Dr, Suite 103, Martinsville, VA 24112

Open in the dashboard

General payments

$9,925

656 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bennett Fein of Martinsville, VA is reported in the CMS Open Payments database as having received $9,925 across 656 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,234 80
2024 General $1,440 86
2023 General $1,556 96
2022 General $1,702 110
2021 General $1,662 124
2020 General $996 67
2019 General $1,334 93

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bennett Fein
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Bennett Fein were reported at $1,234. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Bennett Fein Gastroenterology median Middle half National median
2019 $1,334 $417 $126–$1,100 $163
2020 $996 $224 $74–$624 $114
2021 $1,662 $352 $106–$1,054 $132
2022 $1,702 $448 $129–$1,270 $149
2023 $1,556 $533 $150–$1,390 $160
2024 $1,440 $605 $160–$1,606 $164
2025 $1,234 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,919 210 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $2,239 154 payments
  3. Gilead Sciences, Inc. $919 63 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $866 53 payments
  5. Janssen Biotech, Inc. $632 43 payments
  6. Ardelyx, Inc. $428 29 payments
  7. Celgene Corporation $288 14 payments
  8. Nestle HealthCare Nutrition Inc. $274 17 payments
  9. Intercept Pharmaceuticals, Inc. $268 13 payments
  10. Aimmune Therapeutics, Inc. $181 9 payments
  11. Other $912 51 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,773 651 payments
  2. Education $138 4 payments
  3. Consulting Fee $15 1 payment
Products named General payments · program years 2019–2025
  1. XIFAXAN $1,739 112 payments
  2. LINZESS $1,226 81 payments
  3. CREON $1,109 76 payments
  4. MAVYRET $757 61 payments
  5. VIBERZI $719 47 payments
  6. STELARA $579 40 payments
  7. IBSRELA $428 29 payments
  8. RINVOQ $397 25 payments
  9. ENTYVIO $382 23 payments
  10. TRULANCE $370 31 payments
  11. Other $3,738 215 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

1,431

Median for Gastroenterology: 569

Drug cost

$1,030,393

Median for Gastroenterology: $104,976

Branded share of claims

28.2%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Stelara Ustekinumab Brand 20 $601,789
Xifaxan Rifaximin Brand 53 $180,082
Linzess Linaclotide Brand 126 $96,091
Creon Lipase/Protease/Amylase Brand 32 $77,737
Viberzi Eluxadoline Brand 12 $20,022
Trulance Plecanatide Brand 15 $13,537
Lubiprostone Generic 17 $9,387
Mesalamine Er Mesalamine Brand 25 $7,316
Mesalamine Generic 25 $5,493
Sucralfate Generic 23 $2,528

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$41,557

Medicare's payments for the services billed

Medicare patients

207

Average age 73

Services billed

537

113 women, 94 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 44%
Arthritis 38%
Chronic kidney disease 33%
COPD 26%
Ischemic heart disease 25%
Depression 25%
Atrial fibrillation 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $269
$269 53 —
CREON
  • AbbVie, Inc. $114
$114 32 —
MAVYRET
  • AbbVie, Inc. $101
$101 — —
IBSRELA
  • Ardelyx, Inc. $101
$101 — —
LINZESS
  • AbbVie, Inc. $99
$99 126 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

656 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record